REFERENCES
1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. A novel coro-navirus from patients with pneumonia in China. 2019. N Engl J Med. 2020; 382 (8): 727-33. DOI: http://doi.org/10.1056/NEJMoa2001017
2. Sohag A.A.M., Hannan M.A., Rahman S., Hossain M., Hasan M., Khan M.K., et al. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: a comprehensive review. Drug Dev Res. 2020. DOI: http://doi.org/10.1002/ddr.21709
3. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10 223): 497-506. DOI: http://doi.org/10.1016/S0140-6736(20)30183-5
4. Klasse PJ. Neutralization of virus infectivity by antibodies: old problems in new perspectives. Adv Biol. 2014; 2014: 157895. DOI: http://doi.org/10.1155/2014/157895
5. Coughlin M.M., Prabhakar B.S. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol. 2012; 22 (1): 2-17. DOI: http://doi.org/10.1002/rmv.706
6 Hung I.F., To K.K., Lee C.K., Lee K.L., Chan K., Yan W.W., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52 (4): 447-56. DOI: http://doi.org/10.1093/cid/ciq106
7. Sahr F., Ansumana R., Massaquoi T.A., Idriss B.R., Sesay F.R., Lamin J.M., et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 2017; 74 (3): 302-9. DOI: http://doi.org/10.1016/jjinf.2016.11.009
8. Uyeki T.M., Mehta A.K., Davey R.T. Jr, Liddell A.M., Wolf T., Vetter P., et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016; 374 (7): 636-46. DOI: http://doi.org/10.1056/NEJMoa1504874
9. Zhang J.S., Chen J.T., Liu Y.X., Zhang Z.S., Gao H., Liu Y., et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005; 77 (2): 147-50. DOI: http://doi.org/10.1002/jmv.20431
10. Cheng Y., Wong R., Soo Y.O., Wong W.S., Lee C.K., Ng M.H., et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24 (1): 44-6. DOI: http://doi.org/10.1007/s10096-004-1271-9
11. Casadevall A., Pirofski L.A. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130 (4): 1545-8. DOI: http://doi.org/10.1172/JCI138003
12. Beigel J.H., Voell J., Kumar P., Raviprakash K., Wu H., Jiao J.A., et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018; 18 (4): 410-8. DOI: http://doi.org/10.1016/S1473-3099(18)30002-1
13. Ashour H.M., Elkhatib W.F., Rahman M.M., Elshabrawy H.A. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens. 2020; 9 (3): 186. DOI: http://doi.org/10.3390/pathogens9030186
14. Forster P., Forster L., Renfrew C., Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci USA. 2020; 117 (17): 9241-3. DOI: http://doi.org/10.1073/pnas.2004999117
15. Siu Y.L., Teoh K.T., Lo J., Chan C.M., Kien F., Escriou N., et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. 2008; 82 (22): 11 318-30. DOI: http://doi.org/10.1128/JVI.01052-08
16. Anthony S.J., Johnson C.K., Greig D.J., Kramer S., Che X., Wells H., et al. Global patterns in coronavirus diversity. Virus Evol. 2017; 3 (1): vex012. DOI: http://doi.org/10.1093/ve/vex012
17. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X., et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63 (3): 457-60. DOI: http://doi.org/10.1007/s11427-020-1637-5
18. Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020; 94 (7): e00127-20. DOI: http://doi.org/10.1128/JVI.00127-20
19. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579 (7798): 270-3. DOI: http://doi.org/10.1038/s41586-020-2012-7
20. Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367 (6483): 1260-3. DOI: http://doi.org/10.1126/science.abb2507
21. Liu L., Wei Q., Nishiura K., Peng J., Wang H., Midkiff C., et al. Spa-tiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunol. 2016; 9 (4): 1089-101. DOI: http://doi.org/10.1038/mi.2015.127
22. Tseng C.T., Perrone L.A., Zhu H., Makino S., Peters C.J. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005; 174 (12): 7977-85. DOI: http://doi.org/10.4049/jimmunol.174.12.7977
23. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-9. DOI: http://doi.org/10.1001/jama.2020.1585
24. Chen L., Liu H.G., Liu W., Liu J., Liu K., Shang J., et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43 (3): 203-8. DOI: http://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.013 (in Chinese)
25. Li C., Xu X. Host Immune Responses to SARS Coronavirus in Humans. Molecular Biology of the SARS-Coronavirus. Heidelberg : Springer, 2010.
26. Arabi Y.M., Hajeer A.H., Luke T., Raviprakash K., Balkhy H., Johani S., Al-Dawood A., et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016; 22 (9): 1554-61. DOI: http://doi.org/10.3201/eid2209.151164
27. Roitt I., Brostoff J., Male D. Immunology. 5th ed., London etc., 1998. [Ройт А. Основы иммунологии : пер. с англ. Москва : Мир, 2000. 592 с.]
28. Teixeira da Silva J.A. Convalescent plasma: a possible treatment of COVID-19 in India. Med J Armed Forces India. 2020; 76 (2): 236-7. DOI: http://doi.org/10.1016/j.mjafi.2020.04.006
29. Casadevall A., Pirofski L.A. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003; 24 (9): 474-8. DOI: http://doi.org/10.1016/s1471-4906(03)00228-x
30. Casadevall A., Scharff M.D. Serum therapy revisited: animal models of infection and development of passive antibody therapy. An-timicrob Agents Chemother. 1994; 38 (8): 1695-702. DOI: http://doi.org/10.1128/aac.38.8.1695
31. Gajic O., Rana R., Winters J.L., Yilmaz M., Mendez J.L., Rickman O.B., et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007; 176 (9): 886-91. DOI: http://doi.org/10.1164/rccm.200702-271OC
32. Wan Y., Shang J., Sun S., Tai W., Chen J., Geng Q., et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020; 94 (5): e02015-19. DOI: http://doi.org/10.1128/JVI.02015-19
33. Crowe J.E. Jr, Firestone C.Y., Murphy B.R. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol. 2001; 167 (7): 3910-8. DOI: http://doi.org/10.4049/jimmunol.167.7.3910
34. Zhou G., Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci. 2020; 16 (10): 1718-23. DOI: http://doi.org/10.7150/ijbs.45123
35. Zhang M.Y., Choudhry V., Xiao X., Dimitrov D.S. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Curr Opin Mol Ther. 2005; 7 (2): 151-6.